by Sara M. Nolte | Jun 21, 2023
In addition to showers, flowers and warmer weather, this spring also brought renewed hope for patients with hematological malignancies undergoing stem cell transplants (SCTs) in the form of the approval of Gamida Cell’s Omisirge® (omidubicel). This cell-based therapy...
by Cal Strode | Apr 27, 2023
The first Science Huddle panel discussion of 2023, Cell & Gene Therapy: Maximizing Commercialization, delved into challenges keeping leaders in the cell and gene therapy (CGT) commercialization space up at night. Moderating the event was Dr. Christian K....
by Cal Strode | Mar 29, 2023
Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are...
by Cal Strode | Jan 5, 2023
In 2022, the UK’s Cell and Gene Therapy Catapult (aka CGT Catapult) celebrated its tenth anniversary (congratulations!) marking 10 years of accelerating innovation in cell and gene therapies (CGTs) in the UK. Much like CCRM, CGT Catapult was established as an...
Comments